Difference between revisions of "Farletuzumab (MORAb-003)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the NCI Drug Dictionary: A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets a...") |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | From the NCI Drug Dictionary: A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis. | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/farletuzumab NCI Drug Dictionary]: A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis. |
| + | ==Also known as== | ||
| + | *'''Code name:''' MORAb-003 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:Anti-GP-3 antibodies]] | [[Category:Anti-GP-3 antibodies]] | ||
| + | |||
| + | [[Category:Ovarian cancer medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Latest revision as of 23:48, 31 July 2023
Mechanism of action
From the NCI Drug Dictionary: A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.
Also known as
- Code name: MORAb-003